BioLineRx Ltd. (BLRX) and Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Comparison side by side

This is a contrast between BioLineRx Ltd. (NASDAQ:BLRX) and Titan Pharmaceuticals Inc. (NASDAQ:TTNP) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx Ltd. N/A 0.00 24.67M -0.23 0.00
Titan Pharmaceuticals Inc. 5.44M 3.85 9.46M -0.44 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for BioLineRx Ltd. and Titan Pharmaceuticals Inc.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
BioLineRx Ltd. 0.00% 0% 0%
Titan Pharmaceuticals Inc. -173.90% -904.1% -123.4%

Insider and Institutional Ownership

Institutional investors owned 36.06% of BioLineRx Ltd. shares and 5.7% of Titan Pharmaceuticals Inc. shares. About 4.39% of BioLineRx Ltd.’s share are owned by insiders. Comparatively, insiders own roughly 3.1% of Titan Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioLineRx Ltd. -2.75% -10.11% -26.06% -29.64% -40.1% -39%
Titan Pharmaceuticals Inc. -15.32% -33.4% -58.32% -73.61% -80.71% -78.89%

For the past year BioLineRx Ltd.’s stock price has smaller decline than Titan Pharmaceuticals Inc.

Summary

BioLineRx Ltd. beats Titan Pharmaceuticals Inc. on 5 of the 9 factors.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.